Transforming the Treatment of Neuromuscular Diseases
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
Creating the new generation of genetic therapies
Advancing revolutionary therapies to treat degenerative neuromuscular diseases
Careers at PepGen
We’re seeking passionate individuals who can help us to create therapies to improve the future of people living with neuromuscular diseases
Latest Updates
2022-11-14T08:01:59
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
Read Press Release2022-11-10T08:00:32
PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
Read Press Release2022-11-08T08:01:35
PepGen to Participate in the Stifel 2022 Healthcare Conference
Read Press ReleaseSorry, we couldn't find any posts. Please try a different search.